WO2002017968A3 - Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 - Google Patents

Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 Download PDF

Info

Publication number
WO2002017968A3
WO2002017968A3 PCT/US2001/025663 US0125663W WO0217968A3 WO 2002017968 A3 WO2002017968 A3 WO 2002017968A3 US 0125663 W US0125663 W US 0125663W WO 0217968 A3 WO0217968 A3 WO 0217968A3
Authority
WO
WIPO (PCT)
Prior art keywords
chain
transfection
cancer cells
immunoconjugate
sensitization
Prior art date
Application number
PCT/US2001/025663
Other languages
French (fr)
Other versions
WO2002017968A2 (en
WO2002017968A9 (en
Inventor
Raj K Puri
Original Assignee
Us Gov Health & Human Serv
Raj K Puri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Raj K Puri filed Critical Us Gov Health & Human Serv
Priority to AU2001284978A priority Critical patent/AU2001284978A1/en
Priority to US10/250,998 priority patent/US20040136959A1/en
Publication of WO2002017968A2 publication Critical patent/WO2002017968A2/en
Publication of WO2002017968A3 publication Critical patent/WO2002017968A3/en
Publication of WO2002017968A9 publication Critical patent/WO2002017968A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the discovery that cancer cells that have no or low expression of the IL-13 receptor ('IL-13R') can bind IL-13R-targeted immunoconjugates, such as immunotoxins, by transfection with the IL-13Rα2 chain alone. Transfecting cells with just the IL-13Rα2 chain is easier than transfection with an intact receptor. For some cancers, transfection with the IL-13Rα2 chain alone inhibits tumor growth. Those cancers that are not inhibited by the presence of the IL-13Rα2 chain alone, and which do not express the IL-13R or express it only at low levels can be rendered sensitive to IL-13R-targeted immunoconjugates by transfection of the IL-13α2 chain and can be inhibited by the use of immunoconjugates, such as immunotoxins, targeted to the IL-13R. Nucleic acids encoding the IL-13Rα2 chain or vectors containing such nucleic acids can be used for the manufacture of medicaments to introduce the IL-13Rα2 chain into cancer cells and thereby either inhibit their growth (for cells inhibited by the presence of the IL-13Rα2 chain) or to sensitize them to IL-13R-targeted immunoconjugates, or both.
PCT/US2001/025663 2000-08-31 2001-08-15 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 WO2002017968A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001284978A AU2001284978A1 (en) 2000-08-31 2001-08-15 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain
US10/250,998 US20040136959A1 (en) 2001-08-15 2001-08-15 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il -13 receptor alpha chain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22984200P 2000-08-31 2000-08-31
US60/229,842 2000-08-31

Publications (3)

Publication Number Publication Date
WO2002017968A2 WO2002017968A2 (en) 2002-03-07
WO2002017968A3 true WO2002017968A3 (en) 2002-04-18
WO2002017968A9 WO2002017968A9 (en) 2002-07-04

Family

ID=22862891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025663 WO2002017968A2 (en) 2000-08-31 2001-08-15 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2

Country Status (2)

Country Link
AU (1) AU2001284978A1 (en)
WO (1) WO2002017968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
GB2400662B (en) * 2003-04-15 2006-08-09 Westerngeco Seismic Holdings Active steering for marine seismic sources
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
US9828428B2 (en) 2012-11-07 2017-11-28 Pfizer Inc. Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029417A1 (en) * 1995-03-15 1996-09-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Il-13 receptor specific chimeric proteins and uses thereof
WO2001058479A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029417A1 (en) * 1995-03-15 1996-09-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Il-13 receptor specific chimeric proteins and uses thereof
WO2001058479A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 87, no. 10, 1996, pages 4333 - 4339, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, PURI RAJ K ET AL: "Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of pseudomonas exotoxin A (PE38QQR).", XP002187041, Database accession no. PREV199698827740 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JOSHI, BHARAT H. ET AL: "Preclinical studies with IL-13PE38QQR for therapy of malignant glioma", XP002187040, retrieved from STN Database accession no. 135:316994 HCA *
DEBINSKI W ET AL: "HUMAN GLIOMA CELLS OVEREXPRESS RECEPTORS FOR INTERLEUKIN 13 AND AREEXTREMELY SENSITIVE TO A NOVEL CHIMERIC PROTEIN COMPOSED OF INTERLEUKIN 13 AND PSEUDOMONAS EXOTOXIN 1", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 1, no. 11, 1 November 1995 (1995-11-01), pages 1253 - 1258, XP000579743, ISSN: 1078-0432 *
DRUG NEWS PERSPECT. (2000), 13(10), 599-605 *
JOSHI BHARAT H ET AL: "Interleukin-13 receptor alpha chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.", CANCER RESEARCH, vol. 60, no. 5, 1 March 2000 (2000-03-01), pages 1168 - 1172, XP002946432, ISSN: 0008-5472 *
KAWAKAMI KOJI ET AL: "Gene transfer of interleukin-13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor targeted cytotoxin in an immunodeficient animal model of human prostate cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 42, March 2001 (2001-03-01), 92nd Annual Meeting of the American Association for Cancer Research;New Orleans, LA, USA; March 24-28, 2001, March, 2001, pages 686, XP002187037, ISSN: 0197-016X *
KAWAKAMI KOJI ET AL: "Sensitization of cancer cells to interleukin 13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.", HUMAN GENE THERAPY, vol. 11, no. 13, 1 September 2000 (2000-09-01), pages 1829 - 1835, XP002187039, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
WO2002017968A2 (en) 2002-03-07
AU2001284978A1 (en) 2002-03-13
WO2002017968A9 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
Wingler et al. mRNA stability and selenocysteine insertion sequence efficiency rank gastrointestinal glutathione peroxidase high in the hierarchy of selenoproteins
Sussman et al. Short-term, high-efficiency expression of transfected DNA
Estevez et al. The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development
DE69936061D1 (en) RECOMBINANT VECTOR, EXPRESSING AND USING SEVERAL COSTIMULATORY MOLECULES
YU9403A (en) Anti-dual integrin antibodies, compositions, methods and uses
DE69520149D1 (en) TIE-2 LIGANDE, METHOD FOR THEIR PRODUCTION, AND THEIR APPLICATIONS
JP3747290B2 (en) Enzyme surface expression in gene-directed prodrug therapy
Falkenberg et al. Leading and lagging strand DNA synthesis in vitro by a reconstituted herpes simplex virus type 1 replisome
DE69939109D1 (en) 2,3-OLEFINIC EPOTHILON DERIVATIVES
CN104822705A (en) M971 chimeric antigen receptors
HK1027375A1 (en) Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
Liu et al. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death
DE69504808D1 (en) CORTICOTROPIN RELEASING RECEPTORS OF FACTOR 2
PT939809E (en) TIE-2 RECEIVER LIGANDS (TIE LINK 3 AND TIE LINK 4) AND YOUR USES
WO2002017968A3 (en) Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2
Momparler et al. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside
Roy et al. Survivin modulators: An updated patent review (2011-2015)
Yusa et al. Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene
CN102348796A (en) Novel cancer antigen eEF2
AU2092700A (en) Novel potassium channels and genes encoding these potassium channels
Bala et al. Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene
ES2288318T3 (en) USE OF DNA-PK.
Zhu et al. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate
AU4911000A (en) Novel potassium channels and genes encoding these potassium channels
Watanabe et al. Analysis of protooncogene c-erbB-2 in benign and malignant human prostate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 10250998

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP